Dupilumab (Dupixent)
Also discussed as: dupilumab, Dupilumab, dupixent, Dupixent, syringe injection
STRONG EVIDENCE
72 level-I · 37 level-II · 20 level-IV · 3 level-VI · 2 level-III · 8 level-VII
Research base (design-resolved): 72 systematic review/meta-analysis, 37 randomized trials, 25 observational/descriptive.
very high · 29,506 mentions
Most discussed for: biologic, other, oral_medication
What the research says
Dupilumab significantly improves quality of life and alleviates symptoms in patients with moderate-to-severe atopic dermatitis. (n=6665)
Sun et al. (2025), Frontiers in Pharmacology. doi:10.3389/fphar.2025.1587977 · verifiedDupilumab showed better outcomes than placebo across all efficacy measures.
Liao et al. (2025), PLoS ONE. doi:10.1371/journal.pone.0319400 · verifiedDupilumab was effective in inducing histological remission in EoE patients.
Lutzu et al. (2025), Frontiers in Medicine. doi:10.3389/fmed.2024.1513417 · verifiedDupilumab significantly improved eczema severity scores and reduced itch.
Xiao et al. (2025), Frontiers in Allergy. doi:10.3389/falgy.2025.1668742 · verifiedDupilumab demonstrated significant efficacy in achieving EASI-75 in various age groups.
Zheng et al. (2024), Frontiers in Immunology. doi:10.3389/fimmu.2024.1367099 · verifiedDupilumab is an effective treatment for atopic dermatitis.
Afshari et al. (2024), Frontiers in Immunology. doi:10.3389/fimmu.2024.1361005 · verifiedDupilumab decreases asthma exacerbations and increases lung function in moderate to severe asthma.
Nakagome et al. (2024), Biomolecules. doi:10.3390/biom14050546 · verifiedWhat the community reports
Experience reports, not evidence. Volumes from 1.1M triaged posts.
- biologic
- other
- oral_medication
- topical_prescription
- lifestyle_change
Safety and side effects
Dupilumab may be associated with various side effects, including conjunctivitis, injection-site reactions, headaches, and nasopharyngitis.
For infants and children
Dupilumab is approved for children over 6 months old in the United States and over 6 years old in Europe.
Studied protocols
As reported in the papers, not recommendations.
dose: 300mg; frequency: every 2 weeks; route: subcutaneous
Sroka-Tomaszewska et al. (2021), International Journal of Molecular Sciencesroute: subcutaneous
Szilveszter et al. (2019), Frontiers in Immunologydose: 600 mg loading dose, then 300 mg; frequency: every 2 weeks; route: subcutaneous; duration: 24 weeks
Pelaia et al. (2022), Frontiers in Pharmacologydose: 300 mg; frequency: every 2 weeks; route: subcutaneous; duration: 16 weeks
He et al. (2020), Frontiers in Immunologydose: 300 mg; frequency: every 2 weeks; route: subcutaneous
Makowska et al. (2023), International Journal of Molecular Sciencesdose: 300 mg; frequency: every other week; route: subcutaneous; duration: 52 weeks
Tavecchio et al. (2020), Journal of Clinical MedicineDrawn from 138 papers · generated 2026-06-11T12:39:56.421929+00:00 · phrasing by gpt-4o-mini, every number computed from the database and every citation machine-verified.